

## AMENDMENTS

### In the Specification:

Please amend the paragraph at page 24, line 29 through page 25, line 6 as follows:

For preparation of Mabs and Bi-MAbs, Wistar rats were immunized with  $2 \times 10^7$  Hepa 1-6 cells in CFA. Following three additional boosts with the same cells in ICFA over an 8 week period, spleen cells from immunized rats were fused with YB2/0 rat myelomas as previously described (J. Alan & T. Robin, in: *Immunochemistry in Practice*, Chapter 2 (Blackwell, New York, 2d ed. 1988)). More than twenty Ig-producing hybridomas were selected by immunofluorescent staining. Three antibodies reacted with hepa 1-6 cells by flow cytometry analysis. These Mabs separately recognized a 55 Kd, 95 Kd, 115 Kd or 210 Kd glycoprotein expressed on most tumor cells as determined by immunoprecipitation. The Mabs were designated as anti-gp55 (CCTCC-C200305), anti-gp95 (CCTCC-C200306), anti-gp115 and anti-gp210 (CCTCC-C200307), respectively.

### In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

---

Claims 1-44 (Canceled)

45. (Currently Amended) A method of preparing a pharmaceutical composition or therapeutic vaccine, said method comprising the steps of:

(a) providing a plurality of hepatocellular carcinoma cells, lymphoma cells, colon carcinoma cells or gastric cancer cells;

(b) treating said hepatocellular carcinoma cells, lymphoma cells, colon carcinoma cells or gastric cancer cells to increase the levels of primary or costimulatory molecules in said cells;